Morepen Laboratories Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection at its Masulkhana facility in Himachal Pradesh, with zero observations, marking the fourth consecutive NIL Form 483 inspection for the company over the past eight years.
The inspection, which concluded on 17th April 2026, underscores Morepen’s commitment to maintaining high global quality and regulatory standards. Sanjay Suri, Executive Director of Morepen Laboratories, highlighted that this achievement is a testament to the strength of the company’s quality systems and the discipline of its team in adhering to the highest global standards. This success enhances Morepen’s credibility with global regulators, customers, and partners, paving the way for long-term supply contracts.
The positive outcome of the inspection reflects Morepen’s robust quality management systems, strong data integrity practices, and a deep-rooted culture of regulatory compliance. The company has consistently aligned its operations with evolving global standards, including current ICH and CFR (Part-21) guidelines, ensuring high levels of product quality, safety, and efficacy.
Morepen continues to be a preferred partner for global pharmaceutical companies, successfully catering to regulated markets across the US, Europe, and other geographies. The company exports APIs to over 80 countries, supported by regular and rigorous customer audits. The consistent success in regulatory inspections further reinforces customer confidence and strengthens Morepen’s positioning in highly regulated markets.
In addition to its regulatory achievements, Morepen has significantly invested in digital systems, automation, and data integrity frameworks, ensuring full compliance with global regulatory expectations. The company’s focus on digitalisation enhances traceability, transparency, and operational efficiency across its manufacturing and quality processes.
Morepen is recognised as a market leader in six key Active Pharmaceutical Ingredients (APIs) and is strategically expanding into the Contract Development and Manufacturing Organisation (CDMO) space, leveraging its regulatory track record, infrastructure, and technical expertise.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).